Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06912165
PHASE2

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

Sponsor: Zhejiang Wenda Pharma Technology LTD.

View on ClinicalTrials.gov

Summary

Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2024-12-31

Completion Date

2025-11-30

Last Updated

2025-04-11

Healthy Volunteers

No

Interventions

DRUG

WD-890 tablet

Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG

WD-890 tablet

Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG

WD-890 tablet

Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG

Placebo

Participants will receive placebo QD from Week 0 through Week 16.

Locations (1)

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College

Nanjing, Jiangsu, China